non fda approved glp 1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 FDA approves Lilly's Foundayo (orforglipron)

Common side effects Nausea, especially in the first weeks and after a dose increase Mild constipation or diarrhea Reduced appetite and early fullness Occasional reflux and fatigue in the first weeks Most of these are dose-dependent and improve when we slow the titration pace or adjust how you eat

Promoting Glucose Transporter-4 Vesicle Trafficking Along Cytoskeletal Tracks: PAK-Ing Them Out

But proper treatment can greatly help to improve quality of life for people living with the disease by improving: Pain

Breathing difficulty , especially when lying flat or during mild exertion, combined with weight gain is a potential sign of fluid accumulation around the lungs (pleural effusion) or worsening heart function

Understanding these patterns is the best way to avoid repeating them

What should I do if I see redness, bruising, or a lump at an injection site